BACKGROUND: A cost-effectiveness model that accurately represents disease progression, outcomes, and associated costs is necessary to evaluate the cost-effectiveness of interventions for chronic kidney disease (CKD). STUDY DESIGN: We developed a microsimulation model of the incidence, progression, and treatment of CKD. The model was validated by comparing its predictions with survey and epidemiologic data sources. SETTING & POPULATION: US patients. MODEL, PERSPECTIVE, & TIMEFRAME: The model follows up disease progression in a cohort of simulated patients aged 30 until age 90 years or death. The model consists of 7 mutually exclusive states representing no CKD, 5 stages of CKD, and death. Progression through the stages is governed by a person's glomerular filtration rate and albuminuria status. Diabetes, hypertension, and other risk factors influence CKD and the development of CKD complications in the model. Costs are evaluated from the health care system perspective. INTERVENTION: Usual care, including incidental screening for persons with diabetes or hypertension. OUTCOMES: Progression to CKD stages, complications, and mortality. RESULTS: The model provides reasonably accurate estimates of CKD prevalence by stage. The model predicts that 47.1% of 30-year-olds will develop CKD during their lifetime, with 1.7%, 6.9%, 27.3%, 6.9%, and 4.4% ending at stages 1-5, respectively. Approximately 11% of persons who reach stage 3 will eventually progress to stage 5. The model also predicts that 3.7% of persons will develop end-stage renal disease compared with an estimate of 3.0% based on current end-stage renal disease lifetime incidence. LIMITATIONS: The model synthesizes data from multiple sources rather than a single source and relies on explicit assumptions about progression. The model does not include acute kidney failure. CONCLUSION: The model is well validated and can be used to evaluate the cost-effectiveness of CKD interventions. The model also can be updated as better data for CKD progression become available. Copyright 2010 National Kidney Foundation, Inc. All rights reserved.
BACKGROUND: A cost-effectiveness model that accurately represents disease progression, outcomes, and associated costs is necessary to evaluate the cost-effectiveness of interventions for chronic kidney disease (CKD). STUDY DESIGN: We developed a microsimulation model of the incidence, progression, and treatment of CKD. The model was validated by comparing its predictions with survey and epidemiologic data sources. SETTING & POPULATION: US patients. MODEL, PERSPECTIVE, & TIMEFRAME: The model follows up disease progression in a cohort of simulated patients aged 30 until age 90 years or death. The model consists of 7 mutually exclusive states representing no CKD, 5 stages of CKD, and death. Progression through the stages is governed by a person's glomerular filtration rate and albuminuria status. Diabetes, hypertension, and other risk factors influence CKD and the development of CKD complications in the model. Costs are evaluated from the health care system perspective. INTERVENTION: Usual care, including incidental screening for persons with diabetes or hypertension. OUTCOMES: Progression to CKD stages, complications, and mortality. RESULTS: The model provides reasonably accurate estimates of CKD prevalence by stage. The model predicts that 47.1% of 30-year-olds will develop CKD during their lifetime, with 1.7%, 6.9%, 27.3%, 6.9%, and 4.4% ending at stages 1-5, respectively. Approximately 11% of persons who reach stage 3 will eventually progress to stage 5. The model also predicts that 3.7% of persons will develop end-stage renal disease compared with an estimate of 3.0% based on current end-stage renal disease lifetime incidence. LIMITATIONS: The model synthesizes data from multiple sources rather than a single source and relies on explicit assumptions about progression. The model does not include acute kidney failure. CONCLUSION: The model is well validated and can be used to evaluate the cost-effectiveness of CKD interventions. The model also can be updated as better data for CKD progression become available. Copyright 2010 National Kidney Foundation, Inc. All rights reserved.
Authors: Thomas J Hoerger; John S Wittenborn; Xiaohui Zhuo; Meda E Pavkov; Nilka R Burrows; Paul Eggers; Regina Jordan; Sharon Saydah; Desmond E Williams Journal: J Am Soc Nephrol Date: 2012-12 Impact factor: 10.121
Authors: Joseph Menzin; Lisa M Lines; Daniel E Weiner; Peter J Neumann; Christine Nichols; Lauren Rodriguez; Irene Agodoa; Tracy Mayne Journal: Pharmacoeconomics Date: 2011-10 Impact factor: 4.981
Authors: Andrew S Narva; Michael Briggs; Regina Jordan; Meda E Pavkov; Nilka Rios Burrows; Desmond E Williams Journal: Adv Chronic Kidney Dis Date: 2010-05 Impact factor: 3.620
Authors: Iryna Schlackow; Seamus Kent; William Herrington; Jonathan Emberson; Richard Haynes; Christina Reith; Christoph Wanner; Bengt Fellström; Alastair Gray; Martin J Landray; Colin Baigent; Borislava Mihaylova Journal: Heart Date: 2017-08-05 Impact factor: 5.994
Authors: Nilka Ríos Burrows; Joseph A Vassalotti; Sharon H Saydah; Rebecca Stewart; Monica Gannon; Shu-Cheng Chen; Suying Li; Sarah Pederson; Allan J Collins; Desmond E Williams Journal: Am J Nephrol Date: 2018-11-23 Impact factor: 3.754
Authors: Florin L Craciun; Vanesa Bijol; Amrendra K Ajay; Poornima Rao; Ramya K Kumar; John Hutchinson; Oliver Hofmann; Nikita Joshi; James P Luyendyk; Ulrike Kusebauch; Christopher L Moss; Anand Srivastava; Jonathan Himmelfarb; Sushrut S Waikar; Robert L Moritz; Vishal S Vaidya Journal: J Am Soc Nephrol Date: 2015-10-08 Impact factor: 10.121